Page 50 - IACC Newsletter August-September 2013 Issue 13

Basic HTML Version

India to buy six more C-130J Hercules aircraft from US
India will buy six more C-130J Hercules medium lift aircraft from the United States of America. These aircraft will be
positioned at Panagarh in West Bengal and will be largely dedicated for operations along the India-China border.
The six new C-130J Hercules will cost India an estimated Rs. 4000 crore. The decision to buy the additional six aircraft
was taken by the Defence Acquisition Council (DAC) - the highest decision making body on purchases of the Ministry of
Defence - today. The DAC also cleared the acquisition of another 230 odd Russian made T-90 tanks at a cost of Rs. 6000
crore. These will be produced by the Heavy Vehicles Factory Avadi in Tamil Nadu.
India already has six C-130J aircraft, some which are equipped for special operations. They are based at the Hindon
Airbase on the outskirts of Delhi. The first lot of six aircraft, bought in early 2008, came at cost of about 1.059 billion
dollars (approx Rs. 4,500 crore).
Panagarh is the Headquarters of the newly created Mountain Strike Corps. The C-130J Hercules aircraft can carry about
20 tons at one go and has ability to land at make-shift landing strips.
"With its ability to land almost anywhere, the additional C-130J will give the Mountain Strike Corps ability to move
around troops and rush reinforcements along the front at a very short notice," a senior Ministry of Defence official said.
Recently the C-130J Hercules landed at the Daualt Beg Oldie Advanced Landing ground in Ladakh creating a world record
of sorts for this category of transport planes.
Copyright © NDTV Convergence Limited 2013. All rights reserved.
Lupin gets USFDA nod for insomnia drug
The company has received final approval for its Zolpidem Tartrate Extended-release tablets
Drug major Lupin today said it has received US health regulator's approval to market a generic version of Sanofi Aventis'
Ambien CR Extended-release tablets, used in treating sleep disorders, in the American market.
The company has received final approval from the US Food and Drug Administration (USFDA) for its Zolpidem Tartrate
Extended-release tablets in strengths of 6.25 mg and 12.5 mg, Lupin Ltd said in a statement. "Lupin's wholly-owned US
subsidiary Lupin Pharmaceuticals Inc. shall commence marketing the product shortly," it added.
The product of the Mumbai-based company is indicated for the treatment of insomnia characterized by difficulties with
sleep onset or sleep maintenance. As per the IMS MAT March 2013 sales data, Sanofi's Ambien CR Extended-release
tablets had annual US sales of nearly USD 366 million.
Lupin's cumulative abbreviated new drug application (ANDA) filings with the USFDA stands at 177 with the company
having received 86 approvals as of the quarter ended June 30, 2013.
Copyright © Press Trust of India, All Rights Reserved.